Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Memo Therapeutics secures additional funding, Series C financing now at CHF 45 million

Reading Time: < 1 minute

Memo Therapeutics AG, a biotech company based in Switzerland, has successfully raised an additional CHF 20 million in an extension of its Series C financing, bringing the total amount raised to CHF 45 million. This funding will be used to expand the Phase II trial of its lead asset, AntiBKV, to become the largest study ever conducted for BK virus infection in kidney transplantation.

The BK virus can become reactivated in immunosuppressed kidney transplant patients, leading to severe complications. With no disease-modifying therapies currently available, Memo Therapeutics aims to address this unmet medical need with its highly potent anti-BK virus antibody.

Erik van den Berg, CEO of Memo Therapeutics, expressed his excitement about the financing, stating that it provides further validation of their clinical strategy to bring AntiBKV to patients as quickly as possible. With FDA fast track status already obtained for the product, the company is looking forward to advancing the development of AntiBKV.

New investors Ysios Capital and Kurma Partners participated in the extension round, joining existing investors in supporting Memo Therapeutics’ mission. The company’s pipeline also includes pre-clinical assets in cancer and viral infections, leveraging its antibody discovery platform to develop best-in-class humanized antibodies.

The funding will further support Memo Therapeutics in its efforts to address the urgent need for a treatment for BK virus infection in kidney transplant recipients, as well as other viral infections and oncology indications.

Taylor Swifts New Album Release Health issues from using ACs Boston Marathon 2024 15 Practical Ways To Save Money